Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Intramuscular Immunization Induces Antigen-specific Antibodies in Urine.

Derré L, Lucca I, Cesson V, Valerio M, Cerantola Y, Burruni R, Fritschi U, Gharbi D, Bobst M, Legris AS, Dartiguenave F, Jichlinski P, Nardelli-Haefliger D.

Eur Urol Focus. 2018 Sep 12. pii: S2405-4569(18)30257-8. doi: 10.1016/j.euf.2018.09.003. [Epub ahead of print]

PMID:
30219710
2.

Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice.

Galliverti G, Tichet M, Domingos-Pereira S, Hauert S, Nardelli-Haefliger D, Swartz MA, Hanahan D, Wullschleger S.

Cancer Immunol Res. 2018 Aug 21. doi: 10.1158/2326-6066.CIR-18-0166. [Epub ahead of print]

PMID:
30131378
3.

Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.

Chevalier MF, Schneider AK, Cesson V, Dartiguenave F, Lucca I, Jichlinski P, Nardelli-Haefliger D, Derré L.

Eur Urol. 2018 Nov;74(5):540-544. doi: 10.1016/j.eururo.2018.06.045. Epub 2018 Jul 19.

PMID:
30033046
4.

Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer.

Alvarez-Arguedas S, Uranga S, Martín M, Elizalde J, Gomez AB, Julián E, Nardelli-Haefliger D, Martín C, Aguilo N.

Transl Res. 2018 Jul;197:32-42. doi: 10.1016/j.trsl.2018.03.004. Epub 2018 Apr 6.

PMID:
29702078
5.

Targeting Cx40 (Connexin40) Expression or Function Reduces Angiogenesis in the Developing Mouse Retina.

Haefliger JA, Allagnat F, Hamard L, Le Gal L, Meda P, Nardelli-Haefliger D, Génot E, Alonso F.

Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2136-2146. doi: 10.1161/ATVBAHA.117.310072. Epub 2017 Oct 5.

PMID:
28982669
6.

ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.

Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi AS, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, Derré L.

J Clin Invest. 2017 Aug 1;127(8):2916-2929. doi: 10.1172/JCI89717. Epub 2017 Jun 26.

7.

Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.

Chevalier MF, Bohner P, Pieraerts C, Lhermitte B, Gourmaud J, Nobile A, Rotman S, Cesson V, Martin V, Legris AS, Dartiguenave F, Gharbi D, De Leval L, Speiser DE, Nardelli-Haefliger D, Jichlinski P, Derré L.

Eur Urol. 2017 Jun;71(6):854-857. doi: 10.1016/j.eururo.2016.10.009. Epub 2016 Oct 27.

PMID:
28277277
8.

Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer.

Domingos-Pereira S, Cesson V, Chevalier MF, Derré L, Jichlinski P, Nardelli-Haefliger D.

Oncoimmunology. 2016 Dec 7;6(1):e1265720. doi: 10.1080/2162402X.2016.1265720. eCollection 2017.

9.

Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.

Derré L, Cesson V, Lucca I, Cerantola Y, Valerio M, Fritschi U, Vlamopoulos Y, Burruni R, Legris AS, Dartiguenave F, Gharbi D, Martin V, Vaucher L, Speiser DE, Romero P, Jichlinski P, Nardelli-Haefliger D.

Clin Cancer Res. 2017 Feb 1;23(3):717-725. doi: 10.1158/1078-0432.CCR-16-1189. Epub 2016 Aug 12.

10.

Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer.

Hojeij R, Domingos-Pereira S, Nkosi M, Gharbi D, Derré L, Schiller JT, Jichlinski P, Nardelli-Haefliger D.

Int J Mol Sci. 2016 Jul 14;17(7). pii: E1125. doi: 10.3390/ijms17071125.

11.

Targeting endothelial connexin40 inhibits tumor growth by reducing angiogenesis and improving vessel perfusion.

Alonso F, Domingos-Pereira S, Le Gal L, Derré L, Meda P, Jichlinski P, Nardelli-Haefliger D, Haefliger JA.

Oncotarget. 2016 Mar 22;7(12):14015-28. doi: 10.18632/oncotarget.7370.

12.

High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.

Chevalier MF, Bobisse S, Costa-Nunes C, Cesson V, Jichlinski P, Speiser DE, Harari A, Coukos G, Romero P, Nardelli-Haefliger D, Jandus C, Derré L.

Oncoimmunology. 2015 May 27;4(10):e1029702. eCollection 2015 Oct.

13.

Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor.

Domingos-Pereira S, Hojeij R, Reggi E, Derré L, Chevalier MF, Romero P, Jichlinski P, Nardelli-Haefliger D.

Oncoimmunology. 2015 May 22;4(7):e1016697. eCollection 2015 Jul.

14.

Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Vasilevsky S, Greub G, Nardelli-Haefliger D, Baud D.

Clin Microbiol Rev. 2014 Apr;27(2):346-70. doi: 10.1128/CMR.00105-13. Review.

15.

Restoration of connexin 40 (Cx40) in Renin-producing cells reduces the hypertension of Cx40 null mice.

Le Gal L, Alonso F, Wagner C, Germain S, Nardelli Haefliger D, Meda P, Haefliger JA.

Hypertension. 2014 Jun;63(6):1198-204. doi: 10.1161/HYPERTENSIONAHA.113.02976. Epub 2014 Mar 10.

PMID:
24614215
16.

Immunotherapeutic strategies for bladder cancer.

Chevalier MF, Nardelli-Haefliger D, Domingos-Pereira S, Jichlinski P, Derré L.

Hum Vaccin Immunother. 2014;10(4):977-81. Epub 2014 Jan 2.

17.

Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder.

Domingos-Pereira S, Derré L, Warpelin-Decrausaz L, Haefliger JA, Romero P, Jichlinski P, Nardelli-Haefliger D.

J Urol. 2014 Mar;191(3):814-22. doi: 10.1016/j.juro.2013.08.009. Epub 2013 Aug 13.

PMID:
23954582
18.

Intravaginal live attenuated Salmonella increase local antitumor vaccine-specific CD8+ T cells.

Decrausaz L, Pythoud C, Domingos-Pereira S, Derré L, Jichlinski P, Nardelli-Haefliger D.

Oncoimmunology. 2013 Jan 1;2(1):e22944.

19.

Vaccination route matters for mucosal tumors.

Nardelli-Haefliger D, Dudda JC, Romero P.

Sci Transl Med. 2013 Feb 13;5(172):172fs4. doi: 10.1126/scitranslmed.3005638. No abstract available.

PMID:
23408051
20.

Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.

Domingos-Pereira S, Decrausaz L, Derré L, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D.

Mucosal Immunol. 2013 Mar;6(2):393-404. doi: 10.1038/mi.2012.83. Epub 2012 Sep 12.

21.

Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients.

Pieraerts C, Martin V, Jichlinski P, Nardelli-Haefliger D, Derre L.

Oncoimmunology. 2012 Aug 1;1(5):694-698.

22.

What is the influence of vaccination's routes on the regression of tumors located at mucosal sites?

Nardelli-Haefliger D, Romero P, Jichlinski P.

Oncoimmunology. 2012 Mar 1;1(2):242-243.

23.

SITC 26th annual meeting--summary.

Romano E, Nardelli-Haefliger D, Donda A, Corgnac S, Romero P.

J Transl Med. 2012 May 23;10:105. doi: 10.1186/1479-5876-10-105.

24.

International collaborative proficiency study of Human Papillomavirus type 16 serology.

Eklund C, Unger ER, Nardelli-Haefliger D, Zhou T, Dillner J.

Vaccine. 2012 Jan 5;30(2):294-9. doi: 10.1016/j.vaccine.2011.10.096. Epub 2011 Nov 8.

PMID:
22079074
25.

A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.

Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D.

J Virol. 2011 Dec;85(24):13253-9. doi: 10.1128/JVI.06093-11. Epub 2011 Oct 5.

26.

Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes.

Estrade C, Menoud PA, Nardelli-Haefliger D, Sahli R.

J Clin Microbiol. 2011 Oct;49(10):3474-81. doi: 10.1128/JCM.05039-11. Epub 2011 Aug 10.

27.

Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.

Decrausaz L, Domingos-Pereira S, Duc M, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D.

Int J Cancer. 2011 Aug 1;129(3):762-72. doi: 10.1002/ijc.25973.

28.

A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers.

Decrausaz L, Gonçalves AR, Domingos-Pereira S, Pythoud C, Stehle JC, Schiller J, Jichlinski P, Nardelli-Haefliger D.

Int J Cancer. 2011 May 1;128(9):2105-13. doi: 10.1002/ijc.25561.

29.

Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice.

Decrausaz L, Revaz V, Bobst M, Corthésy B, Romero P, Nardelli-Haefliger D.

Int J Cancer. 2010 May 15;126(10):2469-78. doi: 10.1002/ijc.24949.

30.

Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates.

Berchtold A, Michaud PA, Nardelli-Haefliger D, Surís JC.

Int J Public Health. 2010 Feb;55(1):25-34. doi: 10.1007/s00038-009-0081-3. Epub 2009 Oct 1.

PMID:
19795095
31.

Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.

Fraillery D, Zosso N, Nardelli-Haefliger D.

Vaccine. 2009 Apr 14;27(17):2326-34. doi: 10.1016/j.vaccine.2009.02.029. Epub 2009 Feb 20.

PMID:
19428847
32.

Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.

Stanley M, Gissmann L, Nardelli-Haefliger D.

Vaccine. 2008 Aug 19;26 Suppl 10:K62-7. doi: 10.1016/j.vaccine.2008.05.066. Review.

PMID:
18847558
33.

Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse transcription-PCR.

Revaz V, Debonneville A, Bobst M, Nardelli-Haefliger D.

Clin Vaccine Immunol. 2008 May;15(5):757-64. doi: 10.1128/CVI.00392-07. Epub 2008 Mar 26.

34.

Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.

Echchannaoui H, Bianchi M, Baud D, Bobst M, Stehle JC, Nardelli-Haefliger D.

Infect Immun. 2008 May;76(5):1940-51. doi: 10.1128/IAI.01484-07. Epub 2008 Mar 10.

35.

Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.

Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D.

Clin Vaccine Immunol. 2007 Oct;14(10):1285-95. Epub 2007 Aug 8.

36.

Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.

Revaz V, Zurbriggen R, Moser C, Schiller JT, Ponci F, Bobst M, Nardelli-Haefliger D.

Antiviral Res. 2007 Oct;76(1):75-85. Epub 2007 Jun 19.

PMID:
17617476
37.

Chapter 17: Second generation HPV vaccines to prevent cervical cancer.

Schiller JT, Nardelli-Haefliger D.

Vaccine. 2006 Aug 31;24 Suppl 3:S3/147-53. Epub 2006 Jun 23. Review.

PMID:
16950002
38.

Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.

Nardelli-Haefliger D, Lurati F, Wirthner D, Spertini F, Schiller JT, Lowy DR, Ponci F, De Grandi P.

Vaccine. 2005 May 25;23(28):3634-41.

PMID:
15882523
39.

The importance of mucosal immunity in defense against epithelial cancers.

Revaz V, Nardelli-Haefliger D.

Curr Opin Immunol. 2005 Apr;17(2):175-9. Review.

PMID:
15766678
40.
41.

Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium.

Baud D, Benyacoub J, Revaz V, Kok M, Ponci F, Bobst M, Curtiss R 3rd, De Grandi P, Nardelli-Haefliger D.

Infect Immun. 2004 Feb;72(2):750-6.

42.

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P.

J Natl Cancer Inst. 2003 Aug 6;95(15):1128-37.

PMID:
12902442
44.

Nasal vaccination with attenuated Salmonella typhimurium strains expressing the Hepatitis B nucleocapsid: dose response analysis.

Nardelli-Haefliger D, Benyacoub J, Lemoine R, Hopkins-Donaldson S, Potts A, Hartman F, Kraehenbuhl JP, De Grandi P.

Vaccine. 2001 Apr 6;19(20-22):2854-61.

PMID:
11282196
46.
47.

The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.

Benyacoub J, Hopkins S, Potts A, Kelly S, Kraehenbuhl JP, Curtiss R 3rd, De Grandi P, Nardelli-Haefliger D.

Infect Immun. 1999 Jul;67(7):3674-9.

48.

Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.

Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D.

J Virol. 1998 Oct;72(10):8220-9.

49.

Conserved anterior boundaries of Hox gene expression in the central nervous system of the leech Helobdella.

Kourakis MJ, Master VA, Lokhorst DK, Nardelli-Haefliger D, Wedeen CJ, Martindale MQ, Shankland M.

Dev Biol. 1997 Oct 15;190(2):284-300.

50.

Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P.

Infect Immun. 1997 Aug;65(8):3328-36.

Supplemental Content

Loading ...
Support Center